# OnCo record nct06531291 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06531291/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06531291", "NCT06531291" ;
  schema:name "Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation"@en ;
  schema:description "A phase 2 trial of serplulimab and surufatinib in gallbladder cancer and other biliary tract cancers, run by RenJi Hospital, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06531291/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06531291> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "gallbladder-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/surufatinib/> .